164
Participants
Start Date
January 18, 2023
Primary Completion Date
December 29, 2024
Study Completion Date
December 31, 2025
TGRX-326
Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
Sun Yat-sen University Cancer Center, Guangzhou
Sun Yat-sen University
OTHER
Tongji Hospital
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
West China Hospital
OTHER
Zhejiang University
OTHER
Jilin Provincial Tumor Hospital
OTHER
Hunan Cancer Hospital
OTHER
Shandong Cancer Hospital and Institute
OTHER
Jiangxi Provincial Cancer Hospital
OTHER
First Hospital of China Medical University
OTHER
The Affiliated Hospital of Qingdao University
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Haerbin Medical University Cancer Hospital
UNKNOWN
Xinxiang Central Hospital
OTHER
Xiangyang Central Hospital
OTHER
Mianyang Central Hospital
OTHER
Zhejiang Cancer Hospital
OTHER
Henan Cancer Hospital
OTHER_GOV
First Affiliated Hospital, Sun Yat-Sen University
OTHER
First Affiliated Hospital of Bengbu Medical College
UNKNOWN
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
OTHER
Bingzhou Medical University Affiliated Hospital
UNKNOWN
Fujian Cancer Hospital
OTHER_GOV
Ningbo No. 1 Hospital
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
The Second Affiliated Hospital of AFMU
UNKNOWN
Yunnan Cancer Hospital
OTHER
Capital Medical School Beijing Chest Hospital
UNKNOWN
Shijiazhuang People's Hospital
OTHER
Tianjin Cancer Hospital
UNKNOWN
Affiliated Cancer Hospital of Guizhou Medical University
UNKNOWN
Nanchang University First Affiliated Hospital
UNKNOWN
Jingzhou First People's Hospital
UNKNOWN
Shanghai Chest Hospital
OTHER
Shenzhen TargetRx, Inc.
INDUSTRY